New data release at LINC 2019 reinforces safety profile of low-dose Stellarex DCB

2823

Sean Lyden (Cleveland, USA) and Fabrizio Fanelli (Rome, Italy) discuss the safety and future of drug-coated balloons (DCB) in light of the latest pooled analysis of patient-level data of over 2,300 patients treated with Philips’ Stellarex DCB in above-the-knee studies.

The independent, third party pooled analysis, presented by Lyden at LINC 2019, demonstrated low mortality rates through three years after the treatment with no device-related deaths.

This video is sponsored by Philips.


LEAVE A REPLY

Please enter your comment!
Please enter your name here